Wearable Technologies for Children with Chronic Illnesses: An Exploratory Approach.
Digital tools
Paediatric
Rare disease
Wearable
Journal
Therapeutic innovation & regulatory science
ISSN: 2168-4804
Titre abrégé: Ther Innov Regul Sci
Pays: Switzerland
ID NLM: 101597411
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
01
11
2020
accepted:
17
03
2021
pubmed:
13
4
2021
medline:
6
7
2021
entrez:
12
4
2021
Statut:
ppublish
Résumé
To determine the utility of wearable technologies in physical activity assessment in three paediatric diseases, namely, Niemann-Pick C (NP-C), Juvenile Idiopathic Arthritis (JIA) and Duchenne Muscular Dystrophy (DMD). Exploratory study SETTING AND PATIENTS: Thirty children were recruited across three UK hospitals (Royal Manchester's Children Hospital, Great Ormond Street Children's Hospital, and the Great North Children's Hospital). Ten were diagnosed with NP-C, eight with DMD and twelve with JIA. All participants completed the 6-min walk test (6MWT) at enrolment. Patients were provided with disease-specific smartphone apps paired with a wearable device via Bluetooth. Ambulation was recorded in 30-min epochs measuring average daily maximum (ADM), average daily steps (ADS) and average daily steps per 30-min epoch (ASE). Median 6MWT results were 450 m, 325 m and 434.5 m for the NP-C, DMD and JIA cohorts, respectively. Wearable data capture was feasible in all three disease cohorts, although complete data capture was not sustained. A statistically significant between-cohort difference was identified for ADM, ADS and ASE. Statistically significant differences were found between DMD/JIA for ADM; NP-C/DMD for ADS and DMD/JIA for ASE. Wearable sensor technologies have the potential to provide additional information for our understanding of ambulation in chronic paediatric disease. The wearable devices were easy to use and popular with patients although key features need to be addressed to appropriately meet study objectives. As the technology continues to evolve at a rapid pace, opportunities to implement child friendly solutions are already available.
Identifiants
pubmed: 33844190
doi: 10.1007/s43441-021-00278-9
pii: 10.1007/s43441-021-00278-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
799-806Références
Perry B, Geoghegan C, Lin L, et al. Patient preferences for using mobile technologies in clinical trials. Contemp Clin Trials Commun. 2019;15:100399.
doi: 10.1016/j.conctc.2019.100399
Kristensen PL, Moeller NC, Korsholm L, et al. The association between aerobic fitness and physical activity in children and adolescents: the European youth heart study. Eur J Appl Physiol. 2010;110:267–75.
doi: 10.1007/s00421-010-1491-x
Kashikar-Zuck S, Flowers SR, Verkamp E, et al. Actigraphy-based physical activity monitoring in adolescents with juvenile primary fibromyalgia syndrome. J Pain. 2010;11:885–93.
doi: 10.1016/j.jpain.2009.12.009
Melo HN, Stoots SJ, Pool MA, et al. Objectively measured physical activity levels and sedentary time in children and adolescents with sickle cell anemia. PLoS ONE. 2018;13(12):e0208916.
doi: 10.1371/journal.pone.0208916
Klonoff DC, King F, Kerr D. New opportunities for digital health to thrive. J Diabetes Sci Technol. 2019;13(2):159–63.
doi: 10.1177/1932296818822215
Sim I. Mobile devices and health. N Engl J Med. 2019;381(10):956–68.
doi: 10.1056/NEJMra1806949
Haberkamp M, Moseley J, Athanasiou D, et al. European regulators’ views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials. Neuromuscular Disord. 2019;29(7):514–6.
doi: 10.1016/j.nmd.2019.06.003
European Commission. Communication from the Commission to the European Parliament, The Council, The European Economic and Social Committee and the Committee of the Regions on enabling the digital transformation of health and care in the Digital Single Market; empowering citizens and building a healthier society. Brussels, 25.4.2018 COM. 2018; 233 final.
Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis—why does it vary so much? J Rheumatol. 2002;29:1520–30.
pubmed: 12136914
Hemke R, Nusman CM, van der Heijde DMFM, et al. Frequency of joint involvement in juvenile idiopathic arthritis during a 5-year follow-up of newly diagnosed patients: implication for MR imaging as outcome measure. Rheumatol Int. 2015;35:351–7.
doi: 10.1007/s00296-014-3108-x
Broström E, Haglun-Akerlind Y, Hagelbers S, et al. Gait in children with juvenile chronic arthritis. J Rheumatol. 2002;31:317–23.
Limenis E, Grosbein HA, Feldman BM. The relationship between physical activity levels and pain in children with juvenile idiopathic arthritis. J Rheumatol. 2014;41(2):345–51.
doi: 10.3899/jrheum.130734
Race DL, Sims-Gould J, Tucker LB, et al. “It might hurt, but you have to push through the pain”: perspectives on physical activity from children with juvenile idiopathic arthritis and their parents. J Child Health Care. 2016;20:428–36.
doi: 10.1177/1367493516632616
Patterson MC, Mengel E, Wijburg FA, et al. Longitudinal data from the international registry for Niemann-Pick disease type C (NPC). Mol Genet Metab. 2014. https://doi.org/10.1016/j.ymgme.2013.12.203 .
doi: 10.1016/j.ymgme.2013.12.203
pubmed: 25655951
pmcid: 4390485
Patterson MC, Niemann-Pick Disease Type C. editors GeneReviews® [Internet] Seattle (WA): University of Washington, Seattle; 1993–2019 [Internet]. 2000 Aug 26; In: Adam MP, Ardinger HH, Pagon RA, et al. https://www.ncbi.nlm.nih.gov/books/NBK1296/
Patterson MC, Mengel E, Wijburg FA, et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis. 2013;8(1):12.
doi: 10.1186/1750-1172-8-12
Mah JK, Korngut L, Dykeman J, et al. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014;24(6):482–91.
doi: 10.1016/j.nmd.2014.03.008
Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9(2):177–89.
doi: 10.1016/S1474-4422(09)70272-8
Ricotti V, Ridout DA, Scott E, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosur Ps. 2013;84(6):698–705. https://doi.org/10.1136/jnnp-2012-303902 .
doi: 10.1136/jnnp-2012-303902
A. T. S. Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111–7.
Ulrich S, Hildenbrand F, Treder U, et al. Reference values for the 6-minute walk test in healthy children and adolescents in Switzerland. BMC Pulm Med. 2013;13:49.
doi: 10.1186/1471-2466-13-49
Tudor-Locke C, Craig CL, Beets MW, et al. How many steps/day are enough? For children and adolescents. Int J Behav Nutr Phys Act. 2011;8:78.
doi: 10.1186/1479-5868-8-78
Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep. 1985;100(2):126–31.
pubmed: 3920711
pmcid: 1424733
Lundqvist S, Börjesson M, Larsson MEH, et al. Which patients benefit from physical activity on prescription (PAP)? A prospective observational analysis of factors that predict increased physical activity. BMC Public Health. 2019;19(1):482.
doi: 10.1186/s12889-019-6830-1
Gualano B, Bonfa E, Pereira RMR, et al. Physical activity for paediatric rheumatic diseases: standing up against old paradigms. Nat Rev Rheumatol. 2017;13(6):368–79.
doi: 10.1038/nrrheum.2017.75
Heutinck L, van Kampen N, Jansen M, et al. Physical activity in boys with duchenne muscular dystrophy is lower and less demanding compared to healthy boys. J Child Neurol. 2017;32(5):450–7.
doi: 10.1177/0883073816685506
European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis. 17.
Nijhof LN, van de Putte EM, Wulffraat NM, et al. Prevalence of severe fatigue among adolescents with pediatric rheumatic diseases. Arthritis Care Res. 2015;68(1):108–14.
doi: 10.1002/acr.22710
McErlane F, Foster HE, Carrasco R, et al. Trends in paediatric rheumatology referral times and disease activity indices over a ten-year period among children and young people with Juvenile Idiopathic Arthritis: results from the childhood arthritis prospective Study. Rheumatology (Oxford). 2016;55(7):1225–34.
doi: 10.1093/rheumatology/kew021
The Arthritis Foundation, Childhood Arthritis and Rheumatology Research Alliance. Externally-led juvenile idiopathic arthritis patient-focused drug development meeting report. JIA patient-focused drug development meeting. Washington, DC: 2018.
Fowler EG, Staudt LA, Heberer KR, et al. Longitudinal community walking activity in Duchenne muscular dystrophy. Muscle Nerve. 2018;57(3):401–6.
doi: 10.1002/mus.25743
European Medicines Agency. Qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne Muscular Dystrophy measured by a valid and suitable wearable device. 77.
Rochester L, Mazzà C, Mueller A, et al. A roadmap to inform development, validation and approval of digital mobility outcomes: the mobilise-D approach. Digit Biomark. 2020;4(1):13–27.
doi: 10.1159/000512513